Clinical Watch: May 2019

June 14, 2019

In this issue of Clinical Watch, we discuss the evolution of psoriasis treatment. We suggest criteria for a new biologic for plaque psoriasis and review the albumin-lowering effect of dapagliflozin. Finally, we review claims data to identify potential implications of a new psoriasis treatment.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Article
Digital Enhancements Advance Way2Go Card Solution
Digital Enhancements Advance Way2Go Card Solution

Next Article
Keeping Support Flowing for Families at ERICSA 2019
Keeping Support Flowing for Families at ERICSA 2019